Clinical Trial Update: Nolpitantium Besylate In Patients With Ulcerative Colitis a Double-Blind, Placebo Controlled Efficacy and Safety Study [Phase 2]

View source ↗

Summary

A Phase 2 double-blind, placebo-controlled trial evaluating Nolpitantium Besylate for efficacy and safety in ulcerative colitis has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Bowel Disease
• Ulcerative Colitis

Drugs mentioned

• Nolpitantium Besylate (Nolpitantium Besylate)

Snippet

Sponsor: Sanofi | Conditions: Ulcerative Colitis, Inflammatory Bowel Disease | Phase 2 | Status: COMPLETED